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Summary
 
The molecular mechanisms regulating recruitment of intracellular signaling proteins like
growth factor receptor–bound protein 2 (Grb2), phospholipase C
 
g
 
1, or phosphatidylinositol
3-kinase (PI3-kinase) to the plasma membrane after stimulation of the T cell receptor (TCR)–
CD3–
 
z
 
 complex are not very well understood. We describe here purification, tandem mass
spectrometry sequencing, molecular cloning, and biochemical characterization of a novel trans-
membrane adaptor protein which associates and comodulates with the TCR–CD3–
 
z
 
 complex
in human T lymphocytes and T cell lines. This protein was termed T cell receptor interacting
molecule (TRIM). TRIM is a disulfide-linked homodimer which is comprised of a short ex-
tracellular domain of 8 amino acids, a 19–amino acid transmembrane region, and a 159–amino
acid cytoplasmic tail. In its intracellular domain, TRIM contains several tyrosine-based signal-
ing motifs that could be involved in SH2 domain–mediated protein–protein interactions. In-
deed, after T cell activation, TRIM becomes rapidly phosphorylated on tyrosine residues and
then associates with the 85-kD regulatory subunit of PI3-kinase via an YxxM motif. Thus,
TRIM represents a TCR-associated transmembrane adaptor protein which is likely involved in
targeting of intracellular signaling proteins to the plasma membrane after triggering of the TCR.
Key words: T lymphocytes • T cell receptor • transmembrane adaptor proteins
 
A
 
critical question among several unresolved issues re-
garding the molecular mechanisms leading to T cell
activation is how intracellular signaling molecules like
growth factor receptor–bound protein 2 (Grb2),
 
1
 
 phospho-
lipase C
 
g
 
1, and phosphatidylinositol 3-kinase (PI3-kinase)
are recruited to the plasma membrane after antigen recog-
nition by the TCR. A first clue to how the TCR is con-
nected to downstream signaling pathways was provided by
the recent cloning of a novel phosphoprotein called linker
for activation of T cells (LAT [1]). LAT is a single chain
type III transmembrane protein possessing several tyrosine
motifs in its intracellular domain that are predicted to me-
diate associations with src homology 2 (SH2) domains of
signaling proteins. Indeed, after T cell activation, LAT as-
sociates with a number of intracellular molecules involved
in signal transduction, including Grb2, the 85-kD subunit
of PI3-kinase, phospholipase C
 
g
 
1, SLP76, Sos, and Cbl
(1). Thus, tyrosine-phosphorylated LAT likely targets in-
tracellular proteins to the plasma membrane.
 
1
 
Abbreviations used in this paper:
 
 Grb2, growth factor receptor–bound pro-
tein 2; GST, glutathione-
 
S
 
-transferase; IEF, isoelectric focussing; LAT,
linker for activation of T cells; MAP, mitogen-activated protein; PI3-
kinase, phosphatidylinositol 3-kinase; PTK, protein tyrosine kinase; PTYR,
phosphotyrosine; RACE, rapid amplification of cDNA ends; SH2, src
homology 2; SKAP55, src kinase–associated phosphoprotein of 55 kD;
TRIM, T cell receptor interacting molecule(s).
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The TCR-associated Transmembrane Adaptor Protein TRIM
 
Using two-dimensional isoelectric focussing (IEF)/SDS
gel electrophoresis, we have previously identified a 29/30-kD
disulfide-linked dimer (pp29/30) which is expressed in
resting human T lymphocytes, HPB-ALL cells, and NK
clones (2). Our data suggested that pp29/30 preferentially
associates with the TCR–CD3–
 
z
 
 complex. This conclu-
sion was drawn from experiments in which coprecipitation
of pp29/30 by mAbs directed at signaling receptors ex-
pressed on human T lymphocytes (e.g., CD2 and CD4)
was strongly impaired when expression of the TCR–CD3–
 
z
 
complex was downmodulated by overnight incubation
with a CD3-
 
e
 
 mAb.
We describe here the purification, tandem mass spec-
trometry sequencing, molecular cloning, and biochemical
characterization of pp29/30. pp29/30 is a disulfide-linked
homodimeric transmembrane molecule with a short extra-
cellular domain of eight amino acids which is expressed ex-
clusively in T lymphocytes and NK cells. In T lymphocytes
and T cell lines, pp29/30 coprecipitates and comodulates
with the TCR–CD3–
 
z
 
 complex. Therefore, we termed
the protein T cell receptor interacting molecule (TRIM).
The 159–amino acid intracellular domain of TRIM con-
tains eight tyrosine residues, three of which are compo-
nents of peptide sequence motifs that would be predicted
to be involved in SH2-mediated interaction with intracel-
lular signaling molecules. After T cell activation, TRIM
becomes rapidly tyrosine phosphorylated and is then capa-
ble of associating with the 85-kD regulatory subunit (p85)
of PI3-kinase via an YxxM motif. Thus, TRIM represents
a novel TCR-associated polypeptide likely to be involved
in recruitment of intracellular signaling proteins to the
plasma membrane after T cell activation.
 
Materials and Methods
 
Purification of TRIM.
 
5 
 
3
 
 10
 
9
 
 HPB-ALL cells were washed
once in TBS and lysed in 70 ml of 1% Brij58 lysis buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Brij58 (Pierce Chemical
Co., Rockford, IL), 1 mM NaVanadate, 10 mM NaF, 1 mM
PMSF, 1 
 
m
 
g/ml aprotinin, and 1 
 
m
 
g/ml leupeptin) at 4
 
8
 
C for 2 h.
Postnuclear lysates were consecutively incubated with two ali-
quots of CNBr-activated Sepharose beads (3 ml packed beads)
coupled with the protein A–purified CD3 mAb OKT-3 for 1 h.
The immune complexes were subsequently spun down, and the
beads from the first and second immunoprecipitations were
pooled and washed four times with 10 ml washing buffer (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM NaF, 1 mM PMSF,
0.1% Brij58). An aliquot of 50 
 
m
 
l beads was resuspended in 80 
 
m
 
l
kinase buffer (20 mM Tris-HCl, pH 7.5, 10 mM MnCl, 0.1%
Brij58) supplemented with 20 
 
m
 
Ci [
 
g
 
-
 
32
 
P]ATP (Amersham
Buchler, Braunschweig, Germany), and in vitro phosphorylation
was carried out for 20 min at room temperature. The reaction
was stopped by the addition of 1 ml stop solution (20 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 20 mM EDTA, 0.1% Brij58), and
the radiolabeled beads were washed six times in this buffer.
Radiolabeled and unlabeled beads were pooled and then incu-
bated for 5 min at room temperature under constant agitation
with 5 ml of 100 mM glycine-HCl, pH 2.5 (acidic elution). The
solution was neutralized by the addition of 500 
 
m
 
l of 1.5 M Tris-
 
HCl, pH 8.8, the beads were spun down, the supernatant was
saved, and the beads were washed once with 4 ml washing buffer.
The bead pellet was then resuspended for basic elution in 5 ml of
100 mM triethylamine, pH 11.5, and again incubated for 5 min at
room temperature with agitation. This solution was neutralized
by the addition of 500 
 
m
 
l of 1 M Tris-HCl, pH 7.5, the beads
were spun down, the supernatant was saved, and the beads were
washed once with 4 ml washing buffer. Both eluates and both
washing supernatants were pooled, and eluted proteins were pre-
cipitated overnight at 
 
2
 
20
 
8
 
C by addition of 2.5 vol acetone.
After precipitation, proteins were pelleted for 10 min at 10,000
rpm at 4
 
8
 
C. The protein pellet was washed three times with ice-
cold methanol and dissolved—aided by sonication—in 100 
 
m
 
l lysis
buffer supplemented with 1% Triton X-100. 20 
 
m
 
l of 5
 
3
 
 nonre-
ducing sample buffer was added to this solution, which was incu-
bated for 10 min at 37
 
8
 
C, and the insoluble material was removed
by centrifugation (5 min, 10,000 rpm). The supernatant was then
loaded on the first dimension tube gel of a two-dimensional non-
reducing/reducing SDS-PAGE. After electrophoresis, the gel was
stained with Coomassie blue solution, destained, and subjected to
autoradiography. Protein spots corresponding to pp29/30 were
identified, excised from the gels, and further processed as described
below.
 
Peptide Sequencing.
 
Protein spots corresponding to pp29/30
were excised from four two-dimensional gels stained with Coo-
massie blue. The spots were in-gel digested with trypsin (3), and
the unseparated mixture of recovered tryptic peptides was sub-
jected to nanoelectrospray tandem mass spectrometric sequencing
essentially as described (4). Analyses were performed on a triple
quadrupole mass spectrometer (API III; PE Sciex Instruments,
Ontario, Canada) equipped with the nanoelectrospray ion source
developed by our group (5).
 
cDNA Cloning and Sequencing.
 
Total RNA was isolated from
HPB-ALL cells according to the method of Chomczynski and
Sacchi (6). mRNA was enriched using poly(A) quick columns
(Stratagene, Heidelberg, Germany) according to the manufac-
turer’s protocol and reverse transcribed with MuLV reverse tran-
scriptase (Gibco, Eggenstein, Germany) and an oligo dT(12–18)
primer. This cDNA was used as template for PCR reactions, with
fully redundant oligonucleotides deduced from the 25–amino acid
pp29/30 peptide [AM(L/I)VDSFSPEASGAVEEN(L/I)HDDthk].
L/I stands for leucine/isoleucine; these isobaric amino acids can-
not be distinguished by our method. The underlined amino acids
were used for the generation of forward (GTN GAY AGY TTY
TCN CCN G) and reverse (YTT RTG NGT RTC RTC RTG)
oligonucleotides, respectively. KlenTaq DNA polymerase (Clon-
tech, Palo Alto, CA) was used to amplify the intervening se-
quence. The samples were amplified on a thermocycler (PTC-
200; MJ Research, Watertown, MA) using touchdown programs
with annealing temperature ranges of 55–45 or 50–40
 
8
 
C. A frag-
ment of the expected size was excised from a 4% agarose gel,
cloned into the pCRII vector (Invitrogen Corp., Carlsbad, CA),
and sequenced. The cDNA sequence coding for the internal pep-
tide SQAVEENL was obtained. Comparison of the peptide se-
quence deduced from the cDNA and the actual mass spectrum of
the peptide suggested that two amino acid residues in the internal
peptide were likely miscalled because of the very low intensity of
the ions of the relevant peptide fragments (see Fig. 1).
A forward oligonucleotide (CCA GGC AGT AGA GGA
AAA CAT TC) based on the sequenced internal DNA was then
used together with a lock-docking reverse oligonucleotide
[(T)
 
30
 
VN] in 3
 
9
 
–rapid amplification of cDNA ends (RACE) ex-
periments with cDNA from HPB-ALL poly(A)
 
1
 
 RNA as tem- 
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plate and KlenTaq DNA polymerase (Clontech) in a touchdown
PCR program with an annealing temperature range of 65–55
 
8
 
C.
The resulting DNA fragment was excised from an agarose gel,
cloned into the EcoRV site of the BluescriptII vector (Strat-
agene), and sequenced. It was found to correspond to the 3
 
9
 
 frag-
ment of TRIM, since it contained the nucleotide sequence cod-
ing for the second peptide derived by mass spectrometry [(L/
I)FG(L/I)(L/I)R] as well as the sequence for the very COOH-
terminal part of the 25–amino acid peptide. The amino acid se-
quence HDDPIR was deduced from the cDNA and could be
verified by a comparison of calculated fragment masses and mea-
sured fragment masses in the tandem mass spectrum (see Fig. 1).
The remaining 5
 
9
 
 cDNA was amplified from thymus RACE–
ready cDNA (Clontech) with two nested primers deduced from
the 3
 
9
 
 sequence (CAC CCT GCT GCC AAG TCC TTC TGC
and CAC CAT CCC ATC AAC AAA TGA TCA GG) by
5
 
9
 
-RACE according to the manufacturer’s protocols using touch
down PCR programs and KlenTaq polymerase (Clontech). The
amplified band was purified from an agarose gel and sequenced
directly. When the full-length sequence of TRIM was obtained,
one peptide that was partially sequenced by tandem mass spec-
trometry (MQEATPSAQATNETQMCYASLDHSVK) was addi-
tionally verified via the peptide sequence tag approach (7). Alto-
gether, 56 amino acids in the deduced sequence of TRIM were
verified by tandem mass spectrometry, conclusively confirming
the identity of the protein. All sequencing reactions were per-
formed using the dRhodamine dye terminator chemistry (PE
Applied Biosystems, Foster City, CA) according to the manu-
facturer’s recommendations and analyzed on an automated se-
quencer (model 310; PE Applied Biosystems). Computer-aided
sequence analysis was performed with the HUSAR software
package, which is based on the University of Wisconsin Genetics
Computer Group package (8, 9).
 
Northern Blots.
 
Human multiple-tissue Northern blots and
the human RNA master blot were obtained from Clontech. The
membranes were prehybridized and hybridized at 65
 
8
 
C in 50 mM
Tris-HCl, pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.1% Na
 
4
 
P
 
2
 
O
 
7
 
,
10% dextran sulfate, 1% casein, 1% SDS, and 250 
 
m
 
g/ml salmon
sperm DNA overnight with a TRIM cDNA probe encompassing
nucleotides 1–764. Stringent washes were performed twice at
65
 
8
 
C for 20 min in 60 mM Tris-HCl, pH 8.0, 300 mM NaCl,
2 mM EDTA, 1% SDS, and twice at 65
 
8
 
C for 20 min in 20 mM
Tris-HCl, pH 8.0, 100 mM NaCl, 0.66 mM EDTA, 0.1% SDS.
Blots were then subjected to autoradiography.
 
cDNA Constructs.
 
The chimeric HLA-A2.1–TRIM construct
(chimera_F) consists of the extracellular domain of the HLA class
I allele A2.1 fused to a full-length TRIM molecule (see Fig. 12).
It was generated by separately amplifying the extracellular domain
of the HLA cDNA with an HLA-A2.1–specific forward primer
(ATGGCCGTCATGGCGCCCCG) and a chimeric reverse
primer (GGGGCACCCAGAGATTCCTGAGGGCTGGGA-
AGACGGCTCCC), and the TRIM fragment with an overlap-
ping chimeric forward primer (GGGAGCCGTCTTCCCAGC-
CCTCAGGAATCTCTGGGTGCCCC) and a TRIM-specific
reverse primer (ATGGTCCAGCTAGTTTATAGG). The am-
plified fragments were purified from agarose gels and then used
together as templates for a chimeric PCR with the HLA-A2.1–
specific forward primer and the TRIM–specific reverse primer.
The resulting chimeric DNA fragment was gel purified and
cloned into the BstXI site of the eukaryotic expression vector
pEF-BOS (10). The mutants of chimera_F were produced by
site-directed mutagenesis using the Quick Change site-directed
mutagenesis kit (Stratagene) according to the manufacturer’s pro-
tocol. The following mutants were used in this study: c_F,mut9.4
(Y63 to F, Y110 to F), c_F,mut12.1 (Y
 
79
 
 to F), and c_F,mut15.1
(Y
 
63
 
 to F, Y
 
79
 
 to F, Y
 
110
 
 to F). The sequence of all constructs was
confirmed by DNA sequencing. Transient and stable transfection
of Jurkat cells was performed essentially as described (11).
For the transfection experiments in COS cells, we used the
following cDNA constructs: wild-type fyn cloned in pSR
 
a
 
 ex-
pression vector (provided by Dr. A. da Silva, Dana Farber Cancer
Institute, Boston, MA) and myc-tagged lck or ZAP70 inserted
into pcDNA3 vector (donated by Dr. R. Abraham, The Mayo
Clinic, Rochester, MN).
 
Cells.
 
Jurkat cells, JRT3-T3.5 cells (a Jurkat variant deficient
in expression of the TCR 
 
a
 
 chain, provided by Dr. A. v. Bonin,
Bernard-Nocht Institut für Tropenmedizin, Hamburg, Ger-
many), P116 cells (a Jurkat variant lacking expression of both the
ZAP70 and Syk protein tyrosine kinase [PTK], a gift from Dr. R.
Abraham [12]), HPB-ALL T cells, and COS cells (provided by
Dr. A. da Silva) were maintained in RPMI 1640 (Gibco) supple-
mented with 10% FCS (Gibco), 1% penicillin-streptomycin
(Gibco), and 2% glutamine (Gibco) at 37
 
8
 
C and 100% humidity.
The CD8
 
1
 
 cutaneous T cell lymphoma (PBLCPCS) cell line was
grown in the same medium with the exception that FCS was re-
placed by 10% human serum (Sigma, Deisenhofen, Germany)
and 40 U/ml of recombinant human IL-2 were added (13). PBLs
were prepared by E-rosetting from freshly drawn venous blood of
healthy donors as described elsewhere (14). The Jurkat variant
Pete 2.1 (stably transfected with a full-length A2.1 allele of the
human HLA class I molecule) has been described previously (11).
 
Transfection.
 
2.5 
 
3
 
 10
 
7
 
 Jurkat cells were transfected as de-
scribed previously (11). For transfection of COS cells, 2 
 
3
 
 10
 
5
 
exponentially growing cells were incubated overnight in a six-
well plate (Nunc, Inc., Roskilde, Denmark). Adherent cells were
washed twice with 2 ml of PBS and incubated for 4 h in 1 ml of
transfection solution (2 
 
m
 
g/ml DNA, 10 mg/ml DEAE-dextran,
5.6 mg/ml Chloroquine in RPMI 1640 supplemented with 2%
FCS). The solution was subsequently removed, and 1 ml of a
10% DMSO (Merck, Darmstadt, Germany) in RPMI was added
and allowed to incubate for 2 min. Then cells were washed once
with PBS and incubated for 36 h in 2–3 ml of culture medium.
Transfected cells were washed in PBS and lysed in 250 
 
m
 
l of lysis
buffer.
 
Abs and Inhibitors.
 
The following mAbs were used in immu-
noprecipitation experiments: CD2 (ICRFCD2.1.1A, IgG2a),
CD3-
 
e
 
 (OKT-3, IgG2a), CD4 (AICD4.1, IgG1), CD8 (AICD8.1,
IgG1), CD45 (AICDCD45.2, IgG1), CD28 (8E3B6, IgG1), HLA
class I, allele A2.1 (BB7.2, IgG2a), and antiphosphotyrosine (anti-
PTYR) (PY72, IgG1; a gift from Dr. B. Sefton, The Salk Insti-
tute, San Diego, CA). Typically, proteins were precipitated from
cellular lysates using 25 
 
m
 
l of packed CNBr-Sepharose beads co-
valently coupled with protein A–purified Abs (6 mg Ab/ml packed
beads).
The polyclonal antiserum directed at TRIM was generated by
immunizing rabbits with a KLH-coupled synthetic peptide corre-
sponding to the 25–amino acid long peptide (AMLVDSFSPEAS-
GAVEENLHDDTHK) that was determined by nanoelectrospray
tandem mass spectrometry sequencing of purified pp29/30. The
fact that two 9–amino acid stretches of the 25–amino acid syn-
thetic peptide agreed with the sequence obtained by cDNA se-
quencing proved to be sufficient for specific recognition of
TRIM by the following criteria: (
 
a
 
) ELISA analysis where the an-
tiserum strongly reacted with the wild-type peptide; (
 
b
 
) the spe-
cific reactivity of the antiserum with chimeric TRIM molecules
(e.g., chimera_F) that were transiently or stably expressed in Jur- 
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kat cells; and (
 
c
 
) the specific reactivity of the serum with a wild-
type TRIM molecule that was transiently overexpressed in COS
cells (see Fig. 10).
For Western blot analysis, anti-PTYR (4G10), anti-Grb2, anti–
mitogen-activated protein (MAP), and anti–PI3-kinase mAbs (all
purchased from Upstate Biotechnology Inc., Lake Placid, NY)
were used at 1 
 
m
 
g/ml. Anti-p56
 
lck
 
 and anti-p59
 
fyn 
 
(provided by
Dr. A. Veillette, McGill Cancer Center, McGill University, Mon-
treal, Canada) polyclonal Abs were used at 1:10,000 and 1:2,000
vol/vol dilution, respectively. Mouse mAbs directed at 
 
z
 
 (1C10,
IgG1) and CD3-
 
e
 
 
 
(SP34, IgG3) were donated by Dr. Marcus
Peter, German Cancer Research Center (Heidelberg, Germany),
and used at 1:10,000 (
 
z
 
) and 1:20,000 vol/vol (CD3-
 
e
 
) dilutions.
Affinity-purified polyclonal anti-TRIM antiserum was prepared as
described elsewhere (2) and used at 5–10 
 
m
 
g/ml. For detection of
CD2 in cell lysates, protein A–purified CD2 mAb ICRFCD2.5.1B
(IgG2a) was used at 10 
 
m
 
g/ml. Secondary horseradish peroxidase–
coupled polyclonal antisera were purchased from Dianova GmbH
(Hamburg, Germany) and used at a final dilution of 1:20,000
vol/vol in Western blotting experiments. Anti-TCR mAb C305
(IgM; a gift of Dr. A. Weiss, University of California at San Fran-
cisco, San Francisco, CA) was used as culture supernatant for the
stimulation of Jurkat cells. For inhibition of src-kinase activity,
we preincubated cells for 15 min at 37
 
8
 
C with the recently de-
scribed pyrazolpyrimidine PP1 (reference 15; provided by Dr. S.
Ratnofsky, BASF Bioresearch Corp., Worcester, MA) at a final
concentration of 10 
 
m
 
M before activation with C305 mAb.
 
Comodulation Experiment and In Vitro Activation.
 
To induce mod-
ulation of the TCR–CD3 complex, resting T lymphocytes or
PBLCPCS cells were cultured for 18 h at 37
 
8
 
C in a 1:2 vol/vol
dilution of tissue culture supernatant of anti–CD3-
 
e
 
 mAb (2Ad2A2,
IgM; provided by Dr. E. Reinherz, Dana Farber Cancer Institute)
at a density of 2 
 
3
 
 10
 
6
 
 cells/ml. Expression of cell surface recep-
tors before and after modulation of the TCR–CD3 complex was
assessed by indirect immunofluorescence using a standard proto-
col (14).
In vitro
 
 activation of T cells was performed using a mixture of
biotinylated anti-CD3 plus anti-CD4 mAbs (10 mg/ml). Cells
were incubated for 10 min at 378C with biotinylated Abs which
were then cross-linked for the indicated periods of time by the
addition of avidin (final concentration 80 mg/ml; Sigma). For
Pervanadate treatment, cells were incubated with 0.1 mM Na-
Vanadate (Merck) plus 1 mM H2O2 (Sigma) for 2 min at room
temperature. The cells were washed once in ice-cold TBS, lysed,
and then subjected to precipitation experiments (see below).
Precipitation Experiments. 6 3 107 freshly prepared PBLs or 3 3
107 cells of the various T cell lines were washed once in ice-cold
TBS and then lysed for 1 h at 48C in lysis buffer supplemented
with 1% of detergent (Brij58, Digitonin, Triton X-100 [Sigma],
and NP-40 [Merck]). Postnuclear supernatants were subjected
to immunoprecipitation using 25 ml of CNBr-Sepharose beads
coupled with protein A–purified mAb as described above. For
immunoprecipitation of TRIM, postnuclear lysates were prein-
cubated for 30 min with polyclonal TRIM Ab (1:100 vol/vol),
and immune complexes were then collected with protein A–Seph-
arose (Pharmacia Biotech AB, Uppsala, Sweden). In other experi-
ments, isolated SH2 domains from signaling molecules were ex-
pressed as glutathione-S-transferase (GST) fusion protein and
used for precipitation experiments as described previously (16,
17). The individual precipitates were washed five times in wash-
ing buffer and then either subjected to SDS-PAGE or further
processed for two-dimensional gel electrophoresis, in vitro kinase
assay, or reprecipitation experiments.
In Vitro Kinase Reaction, Two-dimensional Gel Electrophoresis, Re-
precipitation Experiments, and Western Blot Analysis. In vitro ki-
nase reaction, elution of coprecipitated proteins using 1% Triton
X-100 lysis buffer, reprecipitation of in vitro–phosphorylated
proteins, two-dimensional gel electrophoresis, and Western blot
analysis were performed essentially as described previously (2).
For detection of proteins in Western blot experiments, the ECL
detection system (Amersham Buchler) was used. When necessary,
blots were stripped according to the manufacturer’s recommen-
dations and reprobed with additional Abs.
Membrane Preparation. 5 3 107 HPB-ALL cells were washed
twice with TBS and incubated for 45 min in 5 ml of hypotonic
buffer (10 mM Tris, 10 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
20 mg/ml aprotinin, 20 mg/ml leupeptin, 1 mM PMSF, 1 mM
vanadate). Cells were then transferred to a Dounce homogenizer,
and membranes were disrupted by applying 30 strokes on ice.
The homogenate was spun for 20 min at 15,000 rpm in an Ep-
pendorf microfuge, the supernatant was carefully removed, and
the membrane fraction was pelleted by ultracentrifugation (40
min, 33,000 rpm, 48C) using a swing-out rotor (SW55Ti; Beck-
man Instruments Inc., Fullerton, CA). The supernatant was re-
moved (cytosolic fraction), and the pellet (membrane fraction)
was washed twice with 5 ml of ice-cold TBS and then lysed in
100 ml of lysis buffer supplemented with 1% NP-40.
Confocal Laser Scan Microscopy. HBP-ALL T cells were cytospun
onto 3-aminopropyltriethoxysilane–treated slides (Histo-bond slides;
Marienfeld Laboratory Glassware, Bad Mergentheim, Germany)
and fixed in cold acetone for 10 min. After drying, the slides were
incubated for 1 h with a mixture of affinity-purified anti-TRIM
Ab (3 mg/ml) and monoclonal mouse anti–human vimentin
(clone VIM 3B4, isotype IgG2a, dilution 1:2; Camon, Wiesbaden,
Germany). The Abs were diluted in TBS/0.02% BSA with the ad-
dition of 2.5 mg/ml normal human Igs (gamma-venin; Behring-
werke AG, Marburg, Germany). TBS/0.02% BSA was used for all
washing steps and to dilute the secondary and tertiary reagents. As
secondary Abs, a combination of biotinylated goat anti–rabbit IgG
(Dianova GmbH; dilution 1:300 vol/vol) and sheep anti–mouse
IgG1 (1:50 vol/vol) or IgG2a (1:100 vol/vol) Abs (Serotec Ltd.,
Kidlington, UK) plus gamma-venin was used, followed by simul-
taneous incubation with Cy3-conjugated streptavidin (red fluores-
cence, dilution 1:1,000 vol/vol; Dianova GmbH) and Cy2-conju-
gated donkey anti–sheep Abs (green fluorescence, dilution 1:100
vol/vol; Dianova GmbH) for 30 min. After final washes, the sec-
tions were mounted with histogel mounting medium (Camon).
Slides were viewed with a Laserscan microscope (Ernst Leitz
GmbH, Wetzlar, Germany) using 570 nm (red emission) and 508
nm (green emission) filters, respectively. Incubations with omis-
sion of the primary Abs served as negative controls.
Results
Purification of pp29/30 and Generation of a Polyclonal Anti-
serum. To purify pp29/30 (2), CD3-e immunoprecipi-
tates obtained from Brij58 lysates of HPB-ALL cells were
subjected to two-dimensional nonreducing/reducing SDS-
PAGE. Off-diagonal protein spots corresponding to pp29/
30 were excised from the gels and digested with trypsin.
The tryptic fragments were subsequently subjected to tan-
dem mass spectrometry sequencing, which revealed that
the spots contained several individual proteins. Peptides
corresponding to bovine a, b, and k caseins (likely origi-565 Bruyns et al.
nating from culture medium) were rapidly identified by
searching a comprehensive database with the peptide se-
quence tags (7). However, searching protein and expressed
sequence tag (EST) databases with the sequence tags ob-
tained from the other peptide ions did not identify any
known proteins. Therefore, full-length amino acid se-
quences of these peptides were obtained as described previ-
ously (4, 18). Two of the sequenced peptides were en-
coded by expressed sequence tags found in both public and
private databases. Cloning of the corresponding polypep-
tide resulted in the identification of a novel disulfide-linked
dimeric transmembrane adaptor protein (gp30/40) that is
exclusively expressed in lymphocytes (Klode, J., A. Marie-
Cardine, H. Kirchgessner, E. Bruyns, A. Shevchenko, M.
Mann, and B. Schraven, manuscript in preparation). The
other two peptides sequenced (see Materials and Methods,
and Fig. 7) did not match with gp30/40, indicating that they
belonged to an additional protein present in the preparation.
A synthetic peptide corresponding to the 25–amino acid
tryptic fragment sequenced by tandem mass spectrometry (Fig.
1) was coupled to KLH and used to prepare a polyclonal rab-
bit antiserum. Serum obtained from immunized animals but
not the preimmune serum reacts in Western blot with a disul-
fide-linked 60-kD dimer (30 kD reduced) that is expressed in
HPB-ALL cells (Fig. 2 A, left). Perhaps more importantly, this
antiserum exclusively reprecipitates a disulfide-linked 60-kD
dimer from an in vitro–phosphorylated CD3 immunoprecipi-
tate (Fig. 2 A, right) which exactly comigrates with pp29/30 in
two-dimensional IEF/SDS gel electrophoresis (Fig. 2 B). Col-
lectively, these data indicate that the antiserum raised against
the 25–amino acid peptide detects pp29/30.
pp29/30 Coprecipitates and Comodulates with the TCR–
CD3–z Complex in Human T Cells. The availability of a
polyclonal antiserum directed at pp29/30 allowed us to in-
vestigate the molecular relationship between pp29/30 and
the TCR–CD3 complex. To this end, HPB-ALL cells
Figure 1. (Top) Nanoelectrospray tandem mass
spectrometric sequencing of a 25-residue peptide of
pp29/30, showing the tandem mass spectrum ac-
quired from the triply charged ion at m/z 5 900.4.
Collisional fragmentation of triply charged ions of
tryptic peptides typically results in overlapping se-
ries of COOH-terminal peptide fragments (Y-ions)
bearing two positive charges (Y999, bold) or one
positive charge (Y99). The amino acid sequence is
deduced from the spectrum by considering the pre-
cise mass differences between adjacent peptide frag-
ments in conjunction with the known amino acid
molecular weights. The series of doubly charged
Y999-ions allowed determination of the sequence
stretch starting from the NH2 terminus of the pep-
tide (top row). The sequence was then extended to
the COOH terminus by following the series of sin-
gly charged Y99-ions (bottom row), which partially
overlaps with the series of doubly charged frag-
ments. The interpretation algorithm used here relies heavily on the correct identification of the Y-ions among the other fragment ions in the spectrum.
In three regions of the spectrum, the amino acid sequence was called incorrectly, because of the very low intensity of the relevant Y99-ions (ions Y9923,
Y9914, and Y992). Sequence stretches confirmed after the full-length cloning of the protein are in bold, and the regions where the correct sequence was not
obtained are shown in parentheses (the correct sequence determined after the cloning is inside the parentheses in italics). In all cases, the sequence ob-
tained from the cloned protein was consistent with the tandem mass spectrum. Altogether, two contiguous sequence stretches each of nine amino acid
residues were accurately called.
Figure 2. Characterization of
pp29/30. (A) Left, Anti-pp29/30
Western blot analysis (WB) of
HPB-ALL lysates (5 3 105/
lane) under nonreducing and re-
ducing conditions. Crude pp29/
30 antiserum or preimmune se-
rum was used at a 1:500 vol/vol
dilution. For detection, we used
the ECL system (Amersham
Buchler).  Right, and B, Repre-
cipitation experiments (RP). A
CD3 (OKT-3) immunoprecipi-
tate was prepared from HPB-ALL cells (107) lysed in Brij58 containing lysis buffer and subjected to in vitro kinase assay. Phosphorylated proteins were
subsequently released using Triton X-100 lysis buffer. 10% of the material was directly separated on two-dimensional IEF/SDS-PAGE (B, left). The re-
maining material was subjected to reprecipitation using preimmune serum or anti-pp29/30 immune serum. The precipitates were run on nonreducing or
reducing 12% SDS-PAGE (A, right) or were separated on two-dimensional reducing IEF/SDS-PAGE (B, middle and right). Radiolabeled proteins were
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were lysed in buffer containing 1% Digitonin. This treat-
ment preserves the integrity of the TCR–CD3–z complex
while disrupting the weak interactions between the TCR
and coreceptor molecules. Lysates were subjected to im-
munoprecipitation using mAbs directed at different recep-
tor molecules expressed by human T lymphocytes and
subsequently analyzed for coprecipitation of pp29/30 by
anti-pp29/30 Western blotting. Fig. 3 A demonstrates that
under these experimental conditions, pp29/30 exclusively
coprecipitates with the CD3-e molecule but not with the
CD2, CD4, CD8, and CD28 coreceptors and also not with
the CD45 and HLA class I molecules. Similar results as
shown here for HPB-ALL cells were obtained using im-
munoprecipitates from Digitonin lysates of Jurkat T cells as
well as from an IL-2–dependent CD81 subclone of a re-
cently described cutaneous T cell lymphoma (PBLCPCS T
cell line [13]; data not shown). Note that higher molecular
weight forms of pp29/30 are detectable in anti-PTYR im-
munoprecipitates prepared from Pervanadate-treated but
not from unstimulated HPB-ALL cells (Fig. 3 A, PTYR
lanes). This suggests that pp29/30 represents a potential
substrate for PTKs and that its electrophoretic mobility is
influenced by its phosphorylation status (see also Fig. 9).
To further substantiate the association between pp29/30
and the TCR–CD3–z complex, we analyzed the levels of
expression of pp29/30 in untreated PBLCPCS cells and in
PBLCPCS cells in which the TCR–CD3–z complex had
been modulated after overnight incubation with a CD3-e
mAb of the IgM isotype. NP-40 lysates of untreated and
TCR-modulated PBLCPCS cells were separated by reduc-
ing 14% SDS-PAGE, and were analyzed for expression of
pp29/30 using affinity-purified anti-pp29/30 antiserum.
Fig. 3 B demonstrates that expression of pp29/30 is
strongly impaired in TCR-modulated PBLCPCS com-
pared with untreated cells. Densitometric analysis of the
bands corresponding to pp29/30 in untreated versus TCR-
modulated cells revealed a 68% reduction of expression in
the TCR-modulated state. The extent of pp29/30 loss after
modulation of the TCR is similar to that for the z chains,
which showed a 77% reduction in expression in TCR-
modulated cells. In contrast, expression of MAP kinase,
CD8, and HLA class I molecules was not altered after mod-
ulation of the TCR. A similar downregulation of pp29/30
and z as shown for the transformed cell line PBLCPCS was
found in TCR-modulated T lymphocytes. In three inde-
pendent experiments, we observed a 69% average reduc-
tion in expression of pp29/30 and z after modulation of the
TCR–CD3 complex, whereas expression of CD2 and
MAP kinase (Fig. 4), as well as of the CD4, CD8, CD45,
and HLA class I cell surface molecules, remained unaffected
(not shown). In summary, the data shown in Figs. 3 and 4
demonstrate that pp29/30 represents a novel molecule that
associates and comodulates with the TCR–CD3–z com-
plex in T lymphocytes. Therefore, we termed the protein
T cell receptor interacting molecule (TRIM).
70% of Cellular TRIM Associate with the TCR–CD3–z
Complex in PBLCPCS Cells. To investigate the stoichi-
ometry of the interaction between TRIM and the TCR–
CD3 complex, preclearing experiments were performed.
To this end, PBLCPCS cells were lysed in Digitonin and
subjected to five consecutive rounds of immunoprecipita-
tion using an Ab directed at CD3-e. Lysates before and af-
ter the fifth preclearing step were separated on reducing
14% SDS-PAGE and analyzed for the presence of TRIM
by Western blotting. Densitometric analysis of the TRIM-
specific protein bands shown in Fig. 5 A, left, demonstrates
that depletion of CD3 molecules results in a 67% reduction
of detectable TRIM in cell lysates. In contrast, the amounts
of MAP kinase are only slightly reduced after preclearing of
Figure 3. pp29/30 coprecipi-
tates and comodulates with the
TCR–CD3–z complex. (A) Im-
munoprecipitates using mAbs di-
rected at the surface molecules
depicted (top of lanes) were pre-
pared from 3 3 107 HPB-ALL
cells lysed in buffer containing
1% Digitonin. After reducing
14% SDS-PAGE, proteins were
blotted onto nitrocellulose, and
coprecipitation of pp29/30 was
assessed by Western blotting. The first two lanes indicate that pp29/30 is precipitated by an anti-PTYR mAb (PY72) from Pervanadate-treated cells. (B)
PBLCPCS cells were incubated overnight with either culture medium or a 1:2 dilution of culture supernatant of CD3-e mAb 2Ad2A2 (IgM). Expression
of CD3-e (OKT-3), CD8 (AICD8.1), and HLA class I (W6/32) molecules was subsequently determined by indirect immunofluorescence (left). Lysates
corresponding to 5 3 105 nonmodulated (Med.) or modulated (TcR-mod.) cells were separated on reducing 14% SDS-PAGE and blotted onto nitrocellu-
lose (right). Western blot analysis was then performed by consecutive incubation of the nitrocellulose membrane with the Abs depicted (top of lanes).
MAPK, MAP kinase.
Figure 4. Comodulation of pp29/30 with the TCR–CD3–z complex
in T lymphocytes. Postnuclear lysates corresponding to 5 3 106 untreated
or TCR-modulated (TCR-mod.) T lymphocytes of three individual do-
nors were separated on reducing 14% SDS-PAGE. Western blot analysis
was performed by consecutively incubating the nitrocellulose membrane
with the indicated Abs.567 Bruyns et al.
CD3-e. That all CD3-associated TRIM molecules were
successfully depleted by this experimental approach was ev-
ident from the observation that the CD3 immunoprecipi-
tate corresponding to the third preclearing step was already
devoid of any detectable TRIM (and z) (Fig. 5 B). Thus,
z60–70% of all cellular TRIM associate with the TCR–
CD3–z complex in PBLCPCS cells, in agreement with the
comodulation data shown above (Figs. 3 and 4).
The Association between TRIM and Components of the TCR–
CD3–z Complex Occurs at the Cell Membrane. To obtain in-
formation regarding the subcellular localization of TRIM,
membrane and cytosolic fractions of HPB-ALL cells were
analyzed for the presence of TRIM and, as a control, MAP
kinase by Western blotting. As shown in Fig. 6 A, TRIM is
exclusively detectable in the membrane fraction, whereas
MAP kinase is only found in the cytosol. Thus, TRIM
clearly represents a polypeptide associated with cellular
membranes. To address whether TRIM associates with the
TCR at the plasma membrane or exclusively intracellularly
(as described for the TCR–CD3-associated CD3-v chain
[19–22]), a reprecipitation experiment was performed. To
this end, wild-type Jurkat cells and HPB-ALL cells were
incubated on ice for 30 min with a CD3-e mAb of the
IgG2a isotype. Cells were then washed with ice-cold buffer
(to remove all unbound CD3 mAbs) and lysed in Digito-
nin. After depletion of the nuclei, the preformed immune
complexes were collected using protein A–Sepharose and
subjected to in vitro kinase assay. The in vitro–labeled pro-
teins were subsequently released from the primary immu-
noprecipitates using SDS-containing buffer and subjected
to a second round of immunoprecipitation using CD3-e
mAb, z mAb, and TRIM antiserum, respectively. These
secondary immunoprecipitates were separated on reducing
14% SDS-PAGE and analyzed by autoradiography. As a
positive control, we used HPB-ALL cells that were first ly-
sed in Digitonin-containing buffer and then subjected to
CD3 immunoprecipitation, whereas the Jurkat variant
JRT3-T3.1, which is deficient in expression of the TCR a
chain and therefore does not express a CD3 complex on
the cell surface (but expresses identical amounts of CD3-e
as wild-type Jurkat cells intracellularly; data not shown),
was used as a negative control.
Fig. 6 B, top left and bottom left, clearly demonstrates that
TRIM coprecipitates with cell surface–expressed CD3-e in
wild-type Jurkat cells and HPB-ALL cells. This association
seems to be identical to the association detectable in HPB-
ALL cells that are first lysed and then subjected to CD3 im-
munoprecipitation (bottom right). No in vitro–labeled com-
ponents of the TCR–CD3–z complex were reprecipitated
from JRT3-T3.1 cells (top right) under identical experimen-
tal conditions, ruling out the possibility that the externally
applied CD3-e mAb passed the cell membrane. These data
indicate that TRIM associates with the TCR–CD3–z com-
plex at the plasma membrane.
The subcellular localization of TRIM was further as-
sessed by immunofluorescence analysis (Fig. 6 C) of HPB-
ALL cells. To this end, acetone-permeabilized cells were
incubated with TRIM antiserum (red) or an Ab directed at
the cytoskeleton protein vimentin (green). Confocal laser
scan microscopy confirmed the reprecipitation data shown
in Fig. 6 B, namely that a fraction of TRIM localizes at the
plasma membrane. In addition, the molecule seems to ac-
cumulate in a perinuclear region within the cell. Interest-
ingly, a similar subcellular distribution has previously been
described for the transmembrane adaptor molecule LAT (1).
Molecular Cloning of TRIM cDNA. Further analysis of
TRIM required molecular cloning of its corresponding
cDNA. To this end, cDNA prepared from poly(A)1 RNA
of HPB-ALL cells was used as template for touchdown
PCR reactions, with fully redundant oligonucleotides de-
duced from the sequence of the 25–amino acid peptide ob-
tained by tandem mass spectrometry to amplify an internal
fragment of TRIM (coding for SQAVEENI). This se-
quence information was used to clone the rest of the gene
by 59 and 39 RACE. The amino acid sequence of TRIM is
depicted in Fig. 7.
An open reading frame of 558 bp (not shown) codes for
a leaderless transmembrane protein with a calculated mo-
lecular mass of 21 kD that possesses a short 8–amino acid
extracellular domain without potential glycosylation sites, a
19–amino acid transmembrane region lacking charged resi-
dues that presumably serves as signal anchor sequence for
transmembrane transport (23), and a 159–amino acid cyto-
plasmic tail. Transient expression of the TRIM cDNA in
COS cells resulted in the generation of a protein which ex-
actly comigrates with endogenous TRIM derived from
HPB-ALL cells (data not shown, and see Fig. 10). Thus,
the 9-kD difference between the calculated molecular mass
of TRIM and its apparent molecular mass on SDS-PAGE
likely results from posttranslational modifications or insuffi-
cient binding of SDS.
Figure 5. 70% of pp29/30 associates with the TCR–CD3–z complex
in PBLCPCS cells. Digitonin lysates corresponding to 3 3 107 PBLCPCS
cells were consecutively incubated five times with 50 ml of packed
CNBr-Sepharose beads coupled with purified OKT-3. (A) Lysates corre-
sponding to 5 3 105 cells before the first (no precl.) and after the fifth (5x
precl.) preclearing step were separated by reducing 14% SDS-PAGE and
analyzed by anti-pp29/30 and anti–MAP kinase Western blotting. The
densitometric analysis of the individual lanes is indicated. (B) Immuno-
precipitates corresponding to the first (no precl.), the third (3x precl.), and
the fifth (5x precl.) preclearing were blotted onto nitrocellulose and ana-
lyzed for coprecipitation of TRIM and z chains by Western blotting. The
protein bands migrating at 25 and 50 kD (right) represent the heavy and
light chains of the precipitating mouse mAb.568 The TCR-associated Transmembrane Adaptor Protein TRIM
The extracellular domain of TRIM contains one cys-
teine residue (C7) which is most likely responsible for for-
mation of the interchain disulfide bond. In the intracellular
portion, there are two potential phosphorylation sites for
protein kinase C (S116 and S132) and two potential phosphor-
ylation sites for casein kinase 2 (T50 and T151). Note that
S116 is followed by a short stretch of amino acids enriched
in positively charged residues (K118–K127).
Importantly, each chain of TRIM possesses eight ty-
rosine residues in its intracellular portion, at least three of
which could be involved in SH2-mediated interactions
with other signaling proteins. Thus, Y63 and Y110 are part
of YxxL sequences that could bind to the SH2 domains of
src-PTKs, whereas Y79 belongs to a YxxM motif which has
the potential to bind to the SH2 domain of the 85-kD reg-
ulatory subunit of PI3-kinase (24). In summary, the struc-
tural analysis suggests that TRIM could be involved in re-
cruitment of SH2 domain–containing signaling proteins to
the plasma membrane after TCR-mediated activation of T
lymphocytes. Computer-assisted analysis of the TRIM
cDNA and amino acid sequence in all available databases
revealed no obvious homology to any known gene.
TRIM Is Preferentially Expressed in T Lymphocytes and NK
Cells. Expression of the TRIM gene was determined by
Northern blot analysis using a TRIM cDNA probe. The
multiple-tissue Northern blots shown in Fig. 8 demonstrate
that the TRIM transcript is strongly expressed in thymus and
to a lesser extent in spleen, LNs, and PBLs. Note that TRIM
mRNA is already strongly expressed in fetal thymus at weeks
17–24 of gestation (not shown). In contrast, it is undetect-
able in bone marrow and fetal liver, strongly suggesting that
expression of TRIM is restricted to the T cell compartment.
This assumption was confirmed by anti-TRIM Western blot
analysis of cellular lysates prepared from different hematopoi-
etic cell lines. There, TRIM protein was only detectable in
T cell lines but not in B cell lines or in the erythroleukemic
cell line K562 or the monocytic cell line U937 (not shown).
In agreement with our previous data (2), low amounts of
TRIM are detectable in NK cells (not shown). Lack of ex-
pression of TRIM in B lymphocytes was also confirmed by
double staining of histological sections prepared from human
tonsils using TRIM antiserum and a mAb directed at the
CD20 glycoprotein (not shown). In summary, expression of
TRIM is restricted to T and NK cells.
Tyrosine Phosphorylation of TRIM in Response to T Cell Ac-
tivation. As reported above (Fig. 7), the intracellular por-
tion of TRIM possesses several tyrosine-based amino acid
motifs which could recruit SH2 domain–containing pro-
teins to the plasma membrane after T cell activation. One
requirement for such a model is that TRIM represents an
Figure 6. TRIM associates with
the TCR–CD3–z complex at the
cell membrane. (A) Membrane
(lanes 1 and 3) and cytosolic (lanes 2
and 4) fractions were prepared from
HPB-ALL cells, separated on reduc-
ing 14% SDS-PAGE, and blotted
with anti-TRIM polyclonal Ab
(lanes 1 and 2). The blot was then
stripped and reincubated with anti–
MAP kinase Ab (lanes 3 and 4). (B)
3 3 107 intact Jurkat cells (top left),
TCR a chain–deficient JRT3-T3.5
cells (top right), or HPB-ALL cells
(bottom left) were incubated for 30
min on ice with protein A–purified
CD3 mAb (OKT-3). Cells were
washed three times with ice-cold
TBS to remove unbound Abs and
then lysed in 1% Digitonin. Pre-
formed immunocomplexes were
collected with protein A–Sepharose
and subjected to in vitro kinase as-
say. In vitro–phosphorylated pro-
teins were released from the primary
immunoprecipitates and subjected to
reprecipitation using protein A–Seph-
arose alone (lanes 1 and 5), TRIM
antiserum (lanes 2 and 6 ), anti-z
mAb (lanes 3 and 7), or CD3-e mAb
(lanes 4 and 8). Reprecipitated pro-
teins were visualized by autoradiog-
raphy. Bottom right, The same exper-
iment with the exception that cells
(HPB-ALL) were first lysed in Digi-
tonin and then subjected to CD3-e immunoprecipitation. (C) Confocal laser scan microscopy demonstrating plasma membrane localization of TRIM in
HPB-ALL cells. The subcellular localization of TRIM was assessed using affinity-purified polyclonal anti-TRIM Ab (Cy3, red). The green fluorescence
(Cy2) depicts the localization of vimentin. Original magnifications 3600.569 Bruyns et al.
in vivo substrate for PTKs, becoming phosphorylated on
tyrosine residues after triggering of the TCR. To assess this
possibility, HPB-ALL cells were either left unstimulated or
were activated for increasing periods of time using a com-
bination of biotinylated CD3 and CD4 mAbs which were
cross-linked on the cell surface with avidin. A representa-
tive anti-PTYR Western blot of anti-TRIM immunopre-
cipitates prepared from NP-40 lysates of unstimulated or
CD3 3 CD4–activated HPB-ALL cells is shown in Fig. 9,
bottom left. It demonstrates that tyrosine phosphorylation of
TRIM is already detectable after 30 s of T cell activation,
reaches a maximum after 1 min of stimulation, and then
slowly declines within the next 40 min. At all time points,
comparable amounts of the TRIM protein are expressed in
the cells (bottom right). This rules out the possibility that the
differences between resting and activated HPB-ALL cells
are due to altered levels of protein expression rather than
elevated levels of tyrosine phosphorylation. Note that ty-
rosine phosphorylation of TRIM after T cell activation was
also observed in freshly prepared human T lymphocytes as
well as in the Jurkat T cell line stimulated with biotinylated
OKT-3 or anti-TCR mAb C305 alone (not shown, and see
Fig. 10).
Interestingly, the anti-TRIM Ab precipitates two ty-
rosine-phosphorylated 29–30-kD bands from activated HPB-
ALL cells which migrate with slightly different molecular
weights on one-dimensional SDS-PAGE (Fig. 9, bottom
left). This could indicate that several of the eight individual
tyrosine residues in the intracellular portion of TRIM rep-
resent targets for TCR-activated PTKs. That both bands
likely correspond to differentially phosphorylated forms of
TRIM was concluded from the two-dimensional anti-PTYR
Western blot analysis of anti-TRIM immunoprecipitates
prepared from short-term (2 min) activated HPB-ALL cells
shown in Fig. 9, top, B. There, at least three distinct ty-
rosine-phosphorylated spots are detected by anti-PTYR
mAb. Moreover, reprobing the TRIM immunoprecipitates
with anti-TRIM antiserum revealed the appearance of at
least two slightly more acidic TRIM spots in the activated
state (Fig. 9 D, top) compared with the resting state (C, top).
Finally, when anti-PTYR immunoprecipitates prepared
from Pervanadate-treated HPB-ALL cells or from CD3 3
CD4–activated human T lymphocytes were analyzed by
anti-TRIM Western blotting, several differentially ty-
rosine-phosphorylated forms of TRIM were identified
(Fig. 4, and data not shown).
Evidence that TRIM Becomes Phosphorylated by Src-kinases.
The rapid phosphorylation of TRIM on tyrosine residues
suggested that a membrane-proximal tyrosine kinase is re-
sponsible for its phosphorylation after TCR stimulation.
To analyze which tyrosine kinase can phosphorylate TRIM
in vivo, TRIM was transiently expressed in COS cells to-
gether with vectors coding for fyn, lck, or ZAP70 or with a
combination of lck and ZAP70. Lysates of the transfected
cells were analyzed by anti-PTYR Western blotting. In
parallel, anti-PTYR immunoprecipitates were prepared
from the transfected cells and investigated for the presence
of tyrosine-phosphorylated TRIM by anti-TRIM Western
blot. Fig. 10, A and B, demonstrates that under these ex-
perimental conditions, TRIM becomes tyrosine phosphor-
ylated by lck and fyn but not by ZAP70. In addition, con-
comitant expression of lck and ZAP70 does not induce
higher levels of TRIM tyrosine phosphorylation than ex-
pression of lck alone. Also, coexpression of TRIM and Syk
in COS cells did not result in tyrosine phosphorylation of
TRIM (not shown). These data indicate that TRIM could
represent a protein that is preferentially phosphorylated by
tyrosine kinases of the src family. To further substantiate
this assumption, TCR-mediated tyrosine phosphorylation
of TRIM was analyzed in wild-type Jurkat cells and in a
Jurkat variant lacking expression of both ZAP70 and Syk
tyrosine kinases (P116 cells [12]). As shown in Fig. 10 C,
Figure 7. Amino acid sequence of TRIM. The putative transmem-
brane region is boxed. The tyrosine-based signaling motifs are depicted
underneath the corresponding sequence; the peptide sequences obtained
by nanoelectrospray tandem mass spectrometry of purified pp29/30 are
double-underlined. Tyrosine residues are underlined. Note that TRIM
does not possess a leader sequence, and that a cysteine residue is present in
the extracellular domain (C7). The sequence data are available from
EMBL/GenBank under accession no. AJ224878.
Figure 8. Northern blot analysis demonstrating expression of
TRIM in the hematopoietic system. Northern blot analysis was per-
formed on blots containing poly(A)1 RNA from the indicated tissues.
The blots were hybridized with a radiolabeled TRIM cDNA probe
encompassing nucleotides 1–764.570 The TCR-associated Transmembrane Adaptor Protein TRIM
TRIM becomes strongly tyrosine phosphorylated in P116
cells after engagement of the TCR or upon Pervanadate
stimulation. In addition, preincubation of P116 cells with
the recently described inhibitor for src-kinases, PP1 (15),
completely abrogates TCR-mediated tyrosine phosphory-
lation of TRIM. Thus, tyrosine phosphorylation of TRIM
can occur independently of expression of members of the
Syk family PTKs and can be prevented by an inhibitor with
a proposed specificity for src-kinases.
Association of Tyrosine-phosphorylated TRIM with Signaling
Molecules. To assess whether tyrosine-phosphorylated TRIM
could interact with other signaling components of T cells,
the isolated SH2 domains derived from the src-kinases lyn,
fyn, src, and lck, the p85 regulatory subunit of PI3-kinase
(p85), ZAP70, Shc, SLP76, Grb2, SHP1, and SHP2 were
expressed as GST fusion proteins, coupled to glutathione-
Sepharose beads, and incubated with an NP-40 lysate of
short-term (2 min CD3 3 CD4)-treated HPB-ALL cells.
Bound proteins were resolved by SDS-PAGE, transferred
onto nitrocellulose, and probed with anti-TRIM antiserum.
Fig. 11 A demonstrates that tyrosine-phosphorylated TRIM
strongly binds to the isolated SH2 domains of the src-PTKs
lyn, fyn, src, and lck. In addition, TRIM binds to the SH2
domains of the p85 regulatory subunit of PI3-kinase. A
hardly detectable signal is obtained when Grb2 is used for
precipitation, whereas no signal above background levels is
detectable with the SH2 domains of ZAP70, Syk, Shc,
SLP76, SHP1, and SHP2. In addition, no binding of TRIM
to any of the above SH2 domains was observed in nonstimu-
lated cells (not shown). Thus, as predicted from the amino
acid sequence analysis, TRIM in its tyrosine-phosphorylated
state has the capacity to interact with SH2 domains of partic-
ular signaling molecules, namely those of src-PTKs, the p85
regulatory subunit of PI3-kinase, and potentially Grb2.
Figure 9. Tyrosine phosphorylation of TRIM after activation of HPB-
ALL cells. (Top) Analysis of TRIM immunoprecipitates prepared from 6 3
107 unstimulated (A and C) or short-term activated (2 min CD3 3 CD4
co-cross-linking) HPB-ALL cells (B and D) on two-dimensional IEF/
SDS-PAGE. The immunoprecipitates were first analyzed using anti-
PTYR Western blotting (A and B). Membranes were then stripped and
incubated with TRIM antiserum (C and D). (Bottom) 3 3 107 HPB-ALL
cells were incubated for 10 min at 378C with a mixture of biotinylated
CD3 (OKT-3) and CD4 (AICD4.1) mAbs. Cells were then stimulated
for the indicated periods of time by the addition of an appropriate volume
of avidin. Lysates corresponding to 5 3 105 cells were analyzed by anti-
TRIM Western blotting (right). The remaining lysates were subjected to
TRIM immunoprecipitation (IP), resolved on reducing 12% SDS-PAGE,
and blotted with anti-PTYR mAb 4G10 (left).
Figure 10. Evidence that TRIM repre-
sents a substrate for src-kinases. COS cells
were transiently transfected with the cDNA
constructs depicted (top). After lysis, 10% of
the transfected cells were first analyzed by
anti-PYTR Western blotting (A). The
membrane was then stripped, and the ex-
pression of the individual constructs was as-
sessed using anti-TRIM, anti-lck, anti-fyn,
and anti-myc (myc-ZAP70) Abs, respec-
tively (B). The remaining 90% of the lysates
were subjected to anti-PTYR immunopre-
cipitation and analyzed for precipitation of
TRIM by anti-TRIM Western blotting
(PTyr IP). (C) Wild-type (WT) Jurkat cells
or ZAP70/SYK-deficient P116 cells were
either left untreated (Med.) or were preincu-
bated for 15 min with the src-kinase inhibi-
tor PP1 (10 mM). Cells were then
stimulated for 2 min with anti-TCR mAb
C305 in the absence or presence of PP1.
Postnuclear lysates were subjected to immu-
noprecipitation with anti-PTYR mAb
PY72, followed by TRIM immunoblotting.
As a control, cells were incubated for 2 min
with Pervanadate (Perv.).571 Bruyns et al.
To analyze whether tyrosine-phosphorylated TRIM as-
sociates with one of the above identified signaling mole-
cules after T cell activation in vivo, anti-TRIM immuno-
precipitates were obtained from resting or short-term activated
HPB-ALL cells and investigated further by Western blot-
ting using monoclonal or polyclonal Abs directed at p56lck,
p59fyn, p85, and Grb2. As shown in Fig. 11 B, TRIM Ab
coprecipitates the 85-kD subunit of PI3-kinase after T cell
activation. Moreover, low amounts of Grb2 were observed
in TRIM immunoprecipitates prepared from either non-
stimulated or TCR-activated HPB-ALL cells, whereas we
were unable to detect lck or fyn in TRIM immunoprecipi-
tates obtained from either resting or activated lymphocytes
(not shown). Collectively, these data demonstrate that TRIM
possesses the capacity to recruit at least the regulatory p85
subunit of PI3-kinase to the cell surface after triggering of
the TCR.
The Interaction of TRIM with p85 Is Mediated via the YxxM
Motif of TRIM. To investigate whether the interaction be-
tween TRIM and p85 involves one of the three tyrosine-
based signaling motifs of TRIM, we transiently transfected
Jurkat cells with chimeric TRIM molecules that were either
composed of the complete wild-type TRIM molecule
linked to the extracellular domain of the A2.1 allele of the
human HLA class I molecule (chimera_F), or a mutant
thereof in which the tyrosine residues of the Y63xxL, the
Y79xxM, and the Y110xxL motifs of TRIM were mutated to
phenylalanine (chimera_F,mut.15). After overnight incuba-
tion, the transfection efficiency was first assessed by indirect
immunofluorescence (Fig. 12 B, left). Then one half of the
transfected cells was left unstimulated, and the other half was
incubated for 2 min with Pervanadate. Subsequently, anti-
A2.1 immunoprecipitates were prepared from NP-40 lysates
of the transfectants and subjected to Western blot analysis us-
ing PI3-kinase Abs. As a positive control, we used a Jurkat
variant that was stably transfected with chimera_F, whereas a
Jurkat variant that stably expresses a wild-type A2.1 molecule
(Pete 2.1 cell line [11]) served as negative control. Fig. 12 B,
top right, demonstrates that p85 coprecipitates with the wild-
type chimera but not with the TRIM chimera in which ty-
rosines 63, 79, and 110 were mutated to phenylalanine.
To further identify the site within TRIM that is respon-
sible for its binding to p85, A2.1/TRIM chimeras were
transiently expressed in Jurkat cells in which either both
Y63 and Y110 (c_F,mut9.4) or Y79 alone (c_F,mut12.1)
were mutated to phenylalanine (Fig. 12 A). After Pervana-
date treatment of the transfectants, coprecipitation of PI3-
kinase with the chimeric molecules was assessed. Fig. 12 B,
bottom right, depicts that p85 binds to c_F,mut9.4 but not to
c_F,mut12.1. This indicates that the interaction between
TRIM and p85 depends on the presence of the YxxM mo-
tif within the intracytoplasmic tail of TRIM.
Discussion
Signals initiated by binding of MHC-associated peptides
to the TCR are transduced to the intracellular environ-
ment via the TCR-associated CD3 molecules and the z
chains (25–27). Here we describe the molecular cloning
and biochemical characterization of a novel TCR-associ-
ated protein, termed TRIM, which likely participates in
TCR-mediated signal transduction.
The molecular cloning of TRIM was unusually difficult
for a number of reasons. First, the amounts of pp29/30 pro-
tein that could be purified from HPB-ALL cells were rather
low compared with other proteins we have purified recently
(e.g., lymphocyte phosphatase–associated protein [LPAP],
src kinase–associated protein of 55 kD [SKAP55], and
SKAP55 homologue [references 17 and 28, and Marie-Car-
dine, A., A.M. Verhagen, C. Eckerskorn, and B. Schraven,
manuscript submitted for publication]). Second, only sepa-
ration of the CD3 immunoprecipitates on nonreducing/re-
ducing SDS-PAGE allowed the identification of TRIM as
a Coomassie blue–stained protein; this was not possible
when the samples were analyzed on two-dimensional IEF/
SDS-PAGE (not shown). This is most likely due to the fact
that tyrosine-phosphorylated TRIM migrates at a different
position in IEF than nonphosphorylated TRIM (see, for
example, Fig. 9).
The lower resolution of two-dimensional nonreducing/
reducing SDS-PAGE compared with IEF/SDS-PAGE
could be responsible for the fact that the preparation of
Figure 11. Interaction of
TRIM with intracellular signal-
ing molecules. (A) 107 HPB-
ALL cells per lane were activated
for 2 min by cross-linking their
CD3 and CD4 molecules using
biotinylated Abs. Postnuclear ly-
sates of the stimulated cells were
incubated with the recombinant
GST–SH2 domain fusion pro-
teins depicted (top of lanes). Pre-
cipitates were run on reducing
14% SDS-PAGE and subjected
to TRIM Western blotting.
PI3K, PI3-kinase. N 1 C, NH- and COOH-terminal SH2 domains of the corresponding fraction. (B) HPB-ALL cells were either left unstimulated or
were stimulated for 2 min by CD3 3 CD4 cross-linking as described above. Lysates corresponding to 5 3 105 cells were analyzed by anti-PTYR West-
ern blotting (left), and the remaining material was subjected to TRIM immunoprecipitation (IP). Precipitates were run on reducing 12% SDS-PAGE and
subjected to Western blotting using anti-Grb2 or anti-p85 mAbs (right). Note that the Grb2 blot had to be overexposed (five times longer compared with
the p85 blot) to visualize coprecipitation of Grb2.572 The TCR-associated Transmembrane Adaptor Protein TRIM
pp29/30 protein turned out to be composed of a mixture
of at least five polypeptides (three caseins, gp30/40, and
TRIM). Third, of the two tandem mass spectrometry–
derived peptides finally found to belong to TRIM (Figs. 1
and 7), only the 25–amino acid tryptic peptide was suitable
for designing oligonucleotides that could be used in reverse
transcription PCR reactions. Peptides of this size lead to
complicated mass spectra and ambiguities in sequence in-
terpretation (Fig. 1). In the case of TRIM, even though
this was the only suitable peptide in a background of at
least four other proteins, successful cloning was still possi-
ble. Three peptides covering altogether 56 amino acids
were sequenced by tandem mass spectrometry and were
retrospectively matched to the novel protein. Thus, un-
doubtedly, the TRIM molecule described in this paper is
identical to the previously identified pp29/30 polypeptide
that associates with the TCR (2, 29). As we have demon-
strated recently, “de novo” sequencing of large tryptic pep-
tides will now be much facilitated by a novel hybrid quad-
rupole-time-of-flight tandem mass spectrometer that was
not available to us for this investigation (30).
On SDS-PAGE, TRIM migrates with an apparent mo-
lecular mass of 29–30 kD (Fig. 2), which differs from the
calculated mass of 21 kD. This could be the result of post-
translational modifications of TRIM, or might reflect in-
sufficient binding of SDS, which has been reported for
some proteins with acidic isoelectric points. The possibility
that the amino acid sequence reported here is not complete
can be excluded, since transfection of a TRIM cDNA into
COS cells resulted in the expression of a protein that mi-
grates at the same position as endogenous TRIM on SDS-
PAGE (not shown, and Fig. 10).
TRIM is a disulfide-linked dimeric transmembrane protein
which is exclusively expressed in T lymphocytes and NK cells.
It possesses a short extracellular domain of 8 amino acids, a
19–amino acid transmembrane region, and a 159–amino acid
intracytoplasmic tail (Fig. 7). With regard to its expression and
its overall structure, TRIM shares some characteristics with
the z chains. Thus, both proteins are disulfide-linked dimers
with very short extracellular domains. Moreover, both mole-
cules are exclusively expressed in T lymphocytes and NK cells.
The most significant structural difference between TRIM and
z is that TRIM, even though it contains several consensus
tyrosine-phosphorylation motifs, does not possess immunore-
ceptor tyrosine–based activation motifs (Fig. 7).
TRIM also shares structural homology with the recently
described LAT protein (1). Both molecules are type III
transmembrane molecules that have only a very short ex-
tracellular domain and possess a number of potential ty-
rosine-phosphorylation sites in their intracytoplasmic tails
that could mediate binding to SH2 domains of intracellular
signaling molecules. Thus, LAT and TRIM (as well as
gp30/40; Klode, J., A. Marie-Cardine, H. Kirchgessner,
E. Bruyns, A. Shevchenko, M. Mann, and B. Schraven,
manuscript in preparation) define a novel family of trans-
membrane molecules that are likely involved in recruit-
ment of intracellular signaling molecules to the plasma
membrane after TCR stimulation. We suggest terming this
novel family of signaling proteins transmembrane adaptor
proteins (TRAPs).
Figure 12. Binding of p85 to
TRIM requires the YxxM motif.
Jurkat T cells were transiently
transfected with cDNA con-
structs encoding chimeric A2.1–
TRIM molecules (A). Expres-
sion of the chimeras was assessed
by indirect immunofluorescence
using A2.1 mAb BB7.2. In gen-
eral, z28–34% of the transfected
cells expressed the individual
constructs (B, left). Equal num-
bers of alive cells (z1.5–2 3 106
transfected cells expressing the
chimeras) were either left un-
treated or were stimulated for 2
min with Pervanadate. Subse-
quently, cells were lysed in NP-
40 lysis buffer, precipitated with
A2.1 mAb (BB7.2), and sub-
jected to anti–PI3-kinase West-
ern blotting (B, right). Top of
lanes, Individual chimeras.573 Bruyns et al.
Coprecipitation experiments performed under condi-
tions that preserve the integrity of the TCR–CD3–z com-
plex (Fig. 3 A) confirmed our previous assumption that
TRIM physically associates with the TCR. The interaction
between TRIM and the TCR–CD3–z complex was fur-
ther substantiated by our observation that 60–70% of the
TRIM molecules comodulate with the TCR–CD3 com-
plex in T cell lines and PBLs (Fig. 3 B, and Fig. 4). The loss
of detectable TRIM in TCR-modulated cells is quantita-
tively similar to that of z. Whether TRIM becomes in-
ternalized and degraded in TCR-modulated T cells or
whether it is shed from the cell surface in TCR-modulated
cells is not yet clear.
The specificity of TRIM comodulation with the TCR
was further proven by comparative analysis of the expres-
sion levels of CD2, CD8, HLA class I molecules, and MAP
kinase, which clearly did not change upon TCR modula-
tion (Fig. 3 B, and Fig. 4). That the majority of TRIM in-
deed is included in a complex with TCR–CD3–z was
shown in a preclearing experiment where depletion of
CD3-e resulted in an z70% reduction of detectable TRIM
in lysates of PBLCPCS cells (Fig. 5). Thus, TRIM repre-
sents a transmembrane adaptor molecule that associates
with the TCR. The association between TRIM and the
TCR occurs at the level of the plasma membrane, as
judged from laser scan microscopy and from coprecipita-
tion experiments in which TRIM was found to associate
with cell surface–expressed CD3-e (Fig. 6, B and C).
However, these experiments do not exclude the possibility
that TRIM already associates with components of the
TCR–CD3–z complex in the cytoplasm.
The molecular mechanism underlying the interaction
between TRIM and the TCR complex has not yet been
clarified. The CD3 molecules associate with the TCR via
salt bridges formed between oppositely charged amino ac-
ids in the transmembrane regions of the individual proteins
(31). Since TRIM does not possess charged residues in its
transmembrane domain, it has to interact with the TCR–
CD3–z complex via a different molecular mechanism.
It is necessary to mention that despite the fact that
TRIM comodulates with the TCR complex in PBLs, so
far we have not been able to demonstrate coprecipitation of
TRIM with CD3-e in Digitonin lysates of such cells.
Whether this reflects differences in the architecture of the
TCR–CD3–z–TRIM complexes in resting versus prolifer-
ating cells resulting in different susceptibilities toward de-
tergents has to be investigated in further studies. However,
given the high reproducibility of TRIM comodulation
with the TCR in T lymphocytes, the lack of TRIM copre-
cipitation with CD3 does not question its association with
the TCR. In this regard, it has recently been demonstrated
that the z chains associate more loosely with the TCR in
thymocytes than in mature T lymphocytes (32, 33). More-
over, in contrast to T cell hybridomas and T cell lines, the
turnover of z seems to occur independently of the expres-
sion of the other components of the TCR in PBLs (34). It
is possible that a similar situation holds true for the associa-
tion between TRIM and the TCR in various types of cells.
Potential structural differences in the architecture of the
TCR–CD3–z–TRIM complex could also be important in
light of the fact that TRIM is expressed at all stages of T cell
development (ranging from fetal thymocytes of week 14–17
of embryonic development, to adult thymocytes and mature
T cells). If the association between TRIM and the TCR
becomes altered during T cell development and/or T cell acti-
vation, this could result in qualitatively or quantitatively differ-
ent T cell responses after engagement of the TCR. Additional
studies are required to investigate these possibilities.
TRIM becomes tyrosine phosphorylated within seconds
after TCR-mediated T cell activation (Fig. 9). Coexpres-
sion studies performed in COS cells revealed that members
of the src-kinases such as lck and fyn are capable of phos-
phorylating TRIM, whereas ZAP70 and Syk had no influ-
ence on its tyrosine-phosphorylation status under the same
experimental conditions (Fig. 10). Together with the find-
ings that almost identical levels of tyrosine phosphorylation
of TRIM as found in wild-type Jurkat cells are inducible in
a Jurkat variant lacking expression of both Syk and ZAP70
(P116 cells; Fig. 10), and that the recently described src-kinase
inhibitor PP1 (15) completely inhibited TCR-mediated ty-
rosine phosphorylation of TRIM, our data strongly suggest
that TRIM could represent a specific substrate for src-kinases.
However, we certainly cannot exclude the possibility that
particular tyrosine residues of TRIM become phosphory-
lated by Syk and/or ZAP70 after T cell activation.
Three out of the eight potential tyrosine residues in the
intracytoplasmic tail of TRIM are part of sequence motifs
(two YxxL motifs and one YxxM motif [Fig. 7]) which
could interact in the tyrosine-phosphorylated state with the
SH2 domains of intracellular signaling molecules such as
src-kinases and the 85-kD regulatory subunit of PI3-kinase.
Indeed, in short-term activated HPB-ALL cells, tyrosine-
phosphorylated TRIM is coprecipitated by the isolated
SH2 domains of src-kinases and by the SH2 domains of
p85 (Fig. 11 A).
Western blot analysis of TRIM immunoprecipitates pre-
pared from TCR-stimulated HPB-ALL cells revealed an
association between TRIM and p85 that depends on the
activation status of the cells (Fig. 11 B). These data suggest
that TRIM is capable of recruiting p85 to the plasma mem-
brane after TCR-mediated activation of T lymphocytes.
Using chimeric constructs composed of TRIM and the
extracellular domain of the HLA class I molecule A2.1
(chimera_F), we confirmed that the YxxM motif of TRIM
is responsible for its interaction with p85 (Fig. 12). Thus, a
wild-type A2.1–TRIM chimera associated with p85 upon
Pervanadate treatment of Jurkat cells, whereas both a chimera
carrying point mutations in all three tyrosine motifs
(chimera_F,mut15) and a chimera in which tyrosine 79 was
mutated to phenylalanine (chimera_F,mut12.1) failed to
coprecipitate p85 (Fig. 12 B). Our results collectively suggest
that the association between TRIM and p85 is direct and
involves the tyrosine-phosphorylated YxxM motif of TRIM
and the SH2 domains of p85. However, formal proof for
this assumption requires coexpression studies in heterolo-
gous systems or the use of the yeast two-hybrid system.574 The TCR-associated Transmembrane Adaptor Protein TRIM
In contrast to p85, we could not detect either lck or fyn
in TRIM immunoprecipitates obtained from resting or ac-
tivated T cells, although the isolated SH2 domains of the
kinases bound tyrosine-phosphorylated TRIM in vitro.
The latter result is not entirely unexpected, since we have
recently observed that tyrosine-phosphorylated adaptor
proteins like SKAP55 bind to the isolated SH2 domain of
lck, whereas they do not associate with the kinase in intact
cells (17, 29, 35).
It is noteworthy to mention that Y63 is not only a com-
ponent of a signaling motif that potentially binds to SH2
domains of src-kinases; it could also mediate binding to the
SH2 domain of Grb2 (because of the presence of an aspar-
agine in the 12 position). However, although low amounts
of Grb2 consistently coprecipitated with TRIM (see Fig.
11 B, and data not shown), this interaction seems to be of
low stoichiometry and is apparently independent of the ac-
tivation status of the cells. In addition, anti-Grb2 Western
blot analysis of A2.1 immunoprecipitates prepared from Jur-
kat cells transiently transfected with the above A2.1–TRIM
chimeras indicated that Grb2 also binds to the triple ty-
rosine mutant (not shown). This suggests that the Y63xNL
motif does not mediate binding between TRIM and Grb2.
However, we cannot exclude the possibility that the SH2
domain of Grb2 binds to one of the other tyrosine residues
expressed in the intracytoplasmic tail of TRIM, or that
Grb2 binds to TRIM via a sequence motif that does not
involve its SH2 domain. Further studies are required to as-
sess whether Grb2 represents a second intracellular signal-
ing molecule that binds to TRIM.
The function of TRIM has not yet been defined. Tran-
sient overexpression of chimera_F or its mutated versions
in Jurkat cells did not influence TCR-mediated induction
of the nuclear factor of activated T cells (NFAT) and/or
the transcriptional activity of the IL-2 promoter (our un-
published observations). These preliminary data could indi-
cate that TRIM is involved in TCR-mediated signal trans-
duction pathways that do not converge at the level of the
IL-2 gene. Nevertheless, our data suggest that TRIM rep-
resents a novel TCR-associated molecule capable of con-
necting the TCR to the intracellular signaling machinery.
Identification of the signaling pathways in which TRIM
participates will provide novel insights into the membrane
proximal signaling processes involved in T cell growth and
differentiation.
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